Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
In a recent investigation of familial schizophrenia, CBX2 was identified as one of several candidate risk genes in a nuclear family, suggesting a potential role in the pathology of this complex disorder (PMID:37763159). Schizophrenia is characterized by diverse neuropsychiatric symptoms and a high degree of heritability. Although the genetic architecture of schizophrenia is typically polygenic, this study focused on rare, segregating variants that may contribute to disease risk in select families.
Genetic evidence supporting the association comes from a case report in which six rare variants were identified, including a missense change in CBX2, c.1559C>G (p.Ser520Cys), which co-segregated with the schizophrenia phenotype (PMID:37763159). This variant was observed in a single nuclear family, limiting the overall strength of the evidence. In this context, the gene–disease association is currently classified as having Limited evidence, pending further validation in larger cohorts.
The mode of inheritance in the affected family is consistent with an autosomal dominant transmission pattern, with the variant segregating in affected individuals and observed in at least two additional affected relatives. The identified variant c.1559C>G (p.Ser520Cys) alters a conserved residue in CBX2, a gene involved in chromatin remodeling and transcriptional regulation. Detailed molecular analyses indicate that such alterations could feasibly contribute to disruption in gene expression mechanisms relevant to neuropsychiatric conditions.
Functional studies in other contexts have shown that CBX2 plays a critical role in modulating chromatin structure via phosphorylation and nucleosome-binding activity (PMID:28992316, PMID:31093962). Although these experiments were not conducted in neuronal cell models, the mechanistic insights regarding chromatin modulation provide a plausible link to schizophrenia pathogenesis. The relevance of these functional findings supports a Moderate level of functional evidence despite the current limited genetic evidence.
In summary, the integration of genetic and functional data yields a narrative in which a rare, segregating CBX2 variant is implicated in schizophrenia through mechanisms of altered chromatin regulation. While the present evidence is confined to a single nuclear family, it highlights a potential biological mechanism that may have diagnostic utility, informing further targeted research and validation studies.
Key Take‑home: Although the evidence is limited, the identification of a rare CBX2 missense variant combined with supportive functional data suggests a biologically plausible role in schizophrenia that warrants additional investigation.
Gene–Disease AssociationLimitedEvidence is based on a single nuclear family with segregation of a rare variant in CBX2 among affected individuals (PMID:37763159), limiting broad clinical validity. Genetic EvidenceLimitedA rare missense variant, c.1559C>G (p.Ser520Cys), was identified in CBX2 and co-segregated with schizophrenia in one family (PMID:37763159); however, replication in larger cohorts is lacking. Functional EvidenceModerateMultiple in vitro studies demonstrate that CBX2 modulates chromatin dynamics via phosphorylation and nucleosome binding, offering a plausible mechanistic link to the pathogenesis of schizophrenia (PMID:28992316, PMID:31093962). |